Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Block Listing Six Monthly Return

30 Jun 2022 13:29

RNS Number : 8653Q
Diurnal Group PLC
30 June 2022
 

30 June 2022

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Block Listing Six Monthly Return

 

 

Pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies, Diurnal Group plc makes the following update on its block listing:

 

Name of applicant:

Diurnal Group plc

Name of scheme:

Long Term Incentive Plan

Period of return:

From:

17 December 2021

To:

30 June 2022

Balance of unallotted securities under scheme(s) from previous return:

5,775,000

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

665,732

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

5,109,268

 

Name of contact:

Mike Scott

Telephone number of contact:

+44 (0)20 3727 1000

 

 

For further information, please visit www.diurnal.co.uk or contact:

Diurnal Group plc

+44 (0)20 3727 1000

Richard Bungay, Interim Chief Executive Officer

Panmure Gordon (UK) Limited (Nominated Adviser and Joint Corporate Broker)

+44 (0)20 7886 2500

Corporate Finance: Freddy Crossley, Emma Earl

Corporate Broking: Rupert Dearden

 

Stifel Nicolaus Europe Limited (Joint Corporate Broker)

+44 (0) 20 7710 7600

Healthcare Investment Banking: Nicholas Moore, Samira Essebiyea, William Palmer-Brown

Corporate Broking: Nick Adams, Nick Harland

FTI Consulting (Media and Investor Relations)

+44 (0)20 3727 1000

Simon Conway

Victoria Foster Mitchell

Alex Davis

Vane Percy & Roberts (Medical Communications)

+44 (0) 173 782 1890

Simon Vane Percy

 

Notes to Editors

 

About Diurnal Group plc

Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLREAAKEDAPAEFA
Date   Source Headline
7th Mar 20222:30 pmRNSScottish Medicines Consortium Update
2nd Mar 20227:00 amRNSRegulatory update on oral native testosterone
1st Mar 202210:23 amRNSTotal Voting Rights
24th Feb 202212:00 pmRNSNotice of Interim Results
10th Feb 20227:00 amRNSFirst patient dosed in Phase 2 trial
9th Feb 20227:00 amRNSIssue of Long-Term Incentive Plan awards
1st Feb 20227:00 amRNSTotal Voting Rights
31st Jan 20221:26 pmRNSPostponement of R&D Day
26th Jan 20227:00 amRNSTrading Update
24th Jan 20227:00 amRNSDiurnal to participate in Edison “Open House”
11th Jan 20227:00 amRNSOperational update
7th Jan 202212:58 pmRNSHolding(s) in Company
13th Dec 202112:46 pmRNSBlock Admission Application
2nd Dec 20217:00 amRNSNotice of R&D Day
19th Nov 202111:43 amRNSResults of AGM
16th Nov 20217:00 amRNSAlkindi approved for use in Switzerland
15th Nov 20215:20 pmRNSEton enters into US co-promotion deal
15th Nov 20217:00 amRNSDirectorate Change
8th Nov 20219:16 amRNSHolding(s) in Company
15th Oct 202111:17 amRNSHolding(s) in Company
14th Oct 20217:01 amRNSAppointment of Joint Corporate Broker
14th Oct 20217:00 amRNSAgreement signed with ExCEEd Orphan for CEE
11th Oct 20217:00 amRNSPhase 1 data for DITEST published in EJE
8th Oct 202112:24 pmRNSExercise of Options, Issue of Equity and TVR
7th Oct 202111:15 amEQSHardman & Co Research | Diurnal (DNL) Life Sciences Investor Forum
6th Oct 20213:53 pmRNSPosting of Annual Report and Notice of AGM
30th Sep 202112:08 pmRNSHolding(s) in Company
29th Sep 20212:35 pmRNSHolding(s) in Company
17th Sep 20217:00 amRNSHardman & Co Life Sciences Investor Forum
16th Sep 202110:15 amEQSHardman & Co Research: Diurnal Group (DNL): All set for three pivotal trials
15th Sep 20219:17 amRNSDirector Dealings
14th Sep 20217:00 amRNSResults for the year ended 30 June 2021
13th Sep 20217:00 amRNSCommercial launch of Efmody in the UK
1st Sep 20217:00 amRNSDiurnal launches Efmody in Germany and Austria
19th Aug 20217:00 amRNSFull Year Results Investor Presentation
12th Aug 20217:20 amEQSHardman & Co Video Event | Diurnal Group plc - Investor Forum
2nd Aug 20217:00 amRNSGrant of Deferred Share Awards
28th Jul 20217:00 amRNSBusiness and Trading Update
14th Jul 20217:00 amRNSDirector Dealings
12th Jul 20217:00 amRNSAgreement from US FDA on SPA for Chronocort
9th Jul 20218:30 amRNSDirector Dealings and Issue of Equity
7th Jul 20217:00 amRNSNotice of Full Year Results
5th Jul 20217:00 amRNSShares and AJ Bell Investor Evening Webinar
2nd Jul 20217:00 amRNSMarketing Authorisation for Efmody in GB from MHRA
29th Jun 20217:00 amRNSDistribution agreement with Er-Kim
2nd Jun 202112:19 pmRNSDirector Dealings
1st Jun 20217:00 amRNSDiurnal triggers milestone payments from Citrine
28th May 20212:33 pmRNSEuropean Commission approval received for Efmody
13th May 20217:00 amRNSCorrection: Director Dealings
12th May 20215:32 pmRNSDirector Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.